First Complement Inhibitor Wins Full Approval in IgA Nephropathy

(MedPage Today) -- The FDA fully approved iptacopan (Fabhalta) to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression, drugmaker Novartis announced on Friday.
The complement inhibitor...